EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

A Combinatorial Effect of Immune Checkpoint Inhibitors and CD40 Agonistic Antibody in Murine Pancreatic Cancer Model

Juri Ichikawa, Hiroshi Okuda iD, Kuniyuki Kawano, Shingo Kato iD, Shinya Sato iD, Ryo Kuroishikawa, Daisuke Kurotaki, Wataru Kawase, Haruka Yoshida, Yukihiko Hiroshima, Itaru Endo, Shin Maeda iD and 1 more

Cancer Science · 2026

DOI: 10.1111/cas.70246 ↗

At a glance

Journal article in Cancer Science, 2026. Written by Juri Ichikawa and 12 co-authors. Institution: Department of Immunology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan. Major MEDLINE topics: Pancreatic Intraductal Neoplasms, Immune Checkpoint Inhibitors, CD40 Antigens, Antineoplastic Agents, Immunological. Cited 2 times so far (Crossref); 57 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Japan Agency for Medical Research and Development, The research fund from Eisai Co., Ltd., Japan Society for the Promotion of Science.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Pancreatic ductal adenocarcinoma (PDAC) has one of the poorest prognoses of all cancer types. Immune checkpoint inhibitors (ICIs) are currently not indicated for patients with PDAC except for those with high microsatellite instability. In this study, we developed an immunocompetent orthotopic transplant mouse model with Kras and Trp53 mutations, characterized by high fibrosis and an immunosuppressive tumor microenvironment, closely mimicking human PDAC lesions. This model provides a robust platform for investigating strategies for improving ICI efficacy. We observed that ICI monotherapy yielded minimal efficacy, whereas anti‐CD40 agonist antibody (aCD40) monotherapy prolonged survival despite its low impact on primary tumor volume. Moreover, ICIs + aCD40 combination therapy not only extended survival but also significantly reduced tumor burden. These effects were accompanied by enhanced dendritic cell migration to the lymph nodes and T cell priming and activation. Moreover, the expression of immunosuppressive markers in tumor‐associated macrophages was decreased. Indeed, gene expression analyses of infiltrating immune cells have revealed a shift in the tumor microenvironment from an immune‐tolerant state to an immune‐activated state. Our findings suggest that combination therapy with ICIs and aCD40 is a promising treatment strategy for patients with PDAC.

Subjects

MeSH terms (MEDLINE)

Pancreatic Intraductal NeoplasmsImmune Checkpoint InhibitorsCD40 AntigensAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsAnimalsMiceDisease Models, AnimalPancreatic DuctsTumor BurdenDendritic CellsTumor-Associated MacrophagesTumor Microenvironment

Author keywords

CD40 antigenanimaldisease modelsimmune checkpoint inhibitorspancreatic cancertumor microenvironment

Substances

Immune Checkpoint InhibitorsCD40 AntigensAntineoplastic Agents, Immunological

Authors and institutions

  • Department of Immunology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.
  • Department of Gastroenterology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.
  • Department of Clinical Cancer Genomics, Yokohama City University Hospital, Kanagawa, Japan.
  • Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Kanagawa, Japan.
  • Laboratory of Chromatin Organization in Immune Cell Development, International Research Center for Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Advanced Cancer Therapeutics Division, Kanagawa Cancer Center Research Institute, Kanagawa, Japan.

ORCID profiles: Hiroshi Okuda, Shingo Kato, Shinya Sato, Shin Maeda, Tomohiko Tamura

Funding

  • Japan Agency for Medical Research and Development
  • The research fund from Eisai Co., Ltd.
  • Japan Society for the Promotion of Science
  • Support for Pioneering Research Initiated by the Next Generation
  • Strategic Research Promotion at Yokohama City University
  • Yokohama City University research grant "KAMOME Project"

Cite

APA

Ichikawa, J., Okuda, H., Kawano, K., Kato, S., Sato, S., Kuroishikawa, R., Kurotaki, D., Kawase, W., Yoshida, H., Hiroshima, Y., Endo, I., Maeda, S., & Tamura, T. (2026). A Combinatorial Effect of Immune Checkpoint Inhibitors and CD40 Agonistic Antibody in Murine Pancreatic Cancer Model. Cancer Science. https://doi.org/10.1111/cas.70246

Vancouver

Ichikawa J, Okuda H, Kawano K, Kato S, Sato S, Kuroishikawa R, et al. A Combinatorial Effect of Immune Checkpoint Inhibitors and CD40 Agonistic Antibody in Murine Pancreatic Cancer Model. Cancer Science. 2026. doi:10.1111/cas.70246

BibTeX
@article{Ichikawa2026,
  author = {Ichikawa, Juri and Okuda, Hiroshi and Kawano, Kuniyuki and Kato, Shingo and Sato, Shinya and Kuroishikawa, Ryo and Kurotaki, Daisuke and Kawase, Wataru and Yoshida, Haruka and Hiroshima, Yukihiko and Endo, Itaru and Maeda, Shin and Tamura, Tomohiko},
  title = {A Combinatorial Effect of Immune Checkpoint Inhibitors and CD40 Agonistic Antibody in Murine Pancreatic Cancer Model},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70246}
}
Start for free →